Search

Your search keyword '"Corvol, Jean Christophe"' showing total 990 results

Search Constraints

Start Over You searched for: Author "Corvol, Jean Christophe" Remove constraint Author: "Corvol, Jean Christophe"
990 results on '"Corvol, Jean Christophe"'

Search Results

1. Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases

2. Amantadine use in the French prospective NS-Park cohort

3. The impact of subthalamic deep-brain stimulation in restoring motor symmetry in Parkinson’s disease patients: a prospective study

4. Prognosis of impulse control disorders in Parkinson’s disease: a prospective controlled study

5. Genome-wide determinants of mortality and motor progression in Parkinson’s disease

7. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease

10. Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study

11. Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations

12. Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning

15. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

16. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

17. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

18. Personality assessment with Temperament and Character Inventory in Parkinson's disease

19. X-vectors: New Quantitative Biomarkers for Early Parkinson's Disease Detection from Speech

20. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

21. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

22. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression

23. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

25. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

26. The Progressive Supranuclear Palsy Clinical Deficits Scale

27. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

29. Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial

32. Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study

33. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

36. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

37. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease

38. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

39. Neuro-Psychological Outcome of ICU-Admitted COVID-19 Patients Presenting With CNS Complications

41. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

43. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework

45. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease

46. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

47. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.

48. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

49. Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors

50. Association of abnormal explicit sense of agency with cerebellar impairment in myoclonus-dystonia

Catalog

Books, media, physical & digital resources